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Abstract
The recent West Nile virus (WNV) outbreak in the United States underscores the importance of understanding human
immune responses to this pathogen. Via the presentation of viral peptide ligands at the cell surface, class I HLA mediate the
T cell recognition and killing of WNV infected cells. At this time, there are two key unknowns in regards to understanding
protective T cell immunity: 1) the number of viral ligands presented by the HLA of infected cells, and 2) the distribution of T
cell responses to these available HLA/viral complexes. Here, comparative mass spectroscopy was applied to determine the
number of WNV peptides presented by the HLA-A*11:01 of infected cells after which T cell responses to these HLA/WNV
complexes were assessed. Six viral peptides derived from capsid, NS3, NS4b, and NS5 were presented. When T cells from
infected individuals were tested for reactivity to these six viral ligands, polyfunctional T cells were focused on the GTL9 WNV
capsid peptide, ligands from NS3, NS4b, and NS5 were less immunogenic, and two ligands were largely inert, demonstrating
that class I HLA reduce the WNV polyprotein to a handful of immune targets and that polyfunctional T cells recognize
infections by zeroing in on particular HLA/WNV epitopes. Such dominant HLA/peptide epitopes are poised to drive the
development of WNV vaccines that elicit protective T cells as well as providing key antigens for immunoassays that establish
correlates of viral immunity.
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Introduction
West Nile virus (WNV) is a flavivirus that infects avian and
mammalian species, including humans [1]. Symptomatic human
infections exhibit a severe fever and, in some cases, encephalitis
leading to death. Since 1999, more than 30,000 individuals in the
United States have become ill with West Nile virus, and in 2012
forty-eight states have reported a total of 5,387 cases of West Nile
virus disease in people, including 243 deaths [2]. This is the
highest number of West Nile virus disease cases reported in the
United States since 2003, with an unusually high percentage (51%)
of the reported infections classified as neuroinvasive disease (such
as meningitis or encephalitis) [2]. WNV is now endemic in North
America where it continues to inflict considerable morbidity and
mortality [1,3].
Historically, adaptive immune mechanisms effectively control
WNV so that most infections are asymptomatic [4–6]. Humoral
responses directed to the lateral ridge of the WNV envelope
domain III (DIII) are highly neutralizing while humoral responses
to other regions of the envelope, such as the fusion loop of DIII,
are less effective at virus neutralization [7,8]. In instances where
antibodies do not prevent viral entry into host cells, CD8+ T cells
eliminate WNV infected cells. In both humans and in animal
models, CD8+ T cells clear WNV infected cells from the periphery
and central nervous system [9–11]. Through the presentation of
virus-derived peptide epitopes at the plasma membrane, class I
HLA enable CD8+ T cell recognition and cytolysis of infected
cells. Just as with antibody epitopes, the identification of HLA
presented viral peptide epitopes that correspond to protective
immunity is of critical importance for T cell vaccine development
and for establishing correlates of T cell immunity.
At this time, the number and source of viral ligands revealed to
T cells by any given HLA class I molecule has not been tested.
Peptide screening data in humans demonstrate that HLA-A, HLA-
B and HLA-C present immunogenic WNV peptide ligands to T
cells [12,13], but these screening data do not distinguish HLA/
WNV complexes that correlate with protective T cell immunity
from those that do not. Preliminary data with HLA-A*02:01 shows
that a small number of viral ligands are presented to T cells [13]
and that, following infection, T cell responses focus on one
dominant envelope epitope SVG9. Other than SVG9, T cell
responses to other viral ligands were inconsistent and, for some
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A2/WNV ligands, undetectable [13]. Therefore, HLA-A2 distills
WNV to a handful of ligands for T cell review.
Establishing A2/SVG9 as an immunodominant WNV epitope
was key to the development of one WNV vaccine and the testing
of another. A Single Chain Trimer DNA plasmid vaccine
comprised of HLA-A2 and the immunodominant SVG9 WNV
ligand induced robust CD8+ T cell responses, enhanced survival,
and lowered brain viral burden following a lethal WNV challenge
in HLA transgenic mice. The adoptive transfer of these vaccine
induced SVG9-specific CD8+ T cells further protected mice from
an otherwise lethal WNV infections [14]. In humans, vaccination
with a live-attenuated WNV vaccine induced polyfunctional
SVG9-specific CD8+ T cells in 95% of HLA-A*02:01 positive
vaccinated donors, these T cells persisted for a year following
vaccination, and SVG9 responsive T cells lysed cells expressing the
WNV envelope protein and aided in the control of viral replication
[15].
The hypothesis tested here is that, as it is for antibody epitopes,
T cells control WNV infections by focusing on particular viral
ligands while responses to other viral ligands are less correlative
with immune protection. However, the number and nature of viral
fragments presented by class I HLA remains an outstanding
immunologic question, and the goal of this study was to learn how
class I HLA reduce a complex viral proteome to a manageable
number of putative immune epitopes and to learn how T cells
parse reactivity to the available viral ligands. To test this
hypothesis, HLA molecules were gathered from WNV-infected
and uninfected cells and their peptide ligands systematically
compared [16,17]. The results reproduce the observation that
HLA sample a small number of viral peptides dispersed
throughout the flaviviral polyprotein and that T cells focused
upon an immunodominant HLA/WNV epitope can be found in
patients that have resolved their infection. Given immunodomi-
nant WNV T cell epitopes, one can envision the development of
immune therapies and diagnostics with T cells directed towards
these HLA/WNV epitopes.
Results
Six WNV Ligands were presented by Class I HLA-A*11:01
Secreted HLA-A*11:01 class I molecules (sHLA) were gathered
from WNV infected and uninfected cells and utilized as a source of
endogenously loaded peptides for comparative proteomics. Flow
cytometric analysis of the cells producing sHLA confirmed that
one set of peptides in the comparative analysis were derived from
infected cells because viral particles were detected within sHLA
producing cells 12 h after infection of the cells (data not shown). By
day 4, 87% of the cells were infected with WNV (Table 1) and
A*11:01 containing cell supernatant was harvested from infected
cells for days 1 to 5 after infection. sHLA from WNV infected cells
were pooled for affinity chromatography purification and infected
and uninfected A*11:01 yields were 17 mg and 114.9 mg,
respectively, as determined by ELISA.
Peptides eluted from HLA class I molecules contain thousands
of different peptide constituents. Prior to comparative mass
spectrometric analysis, peptide complexity was reduced by reverse
phase HPLC (RP-HPLC) into fractions containing approximately
200–250 peptides each (Figure 1A). Similar HPLC elution patterns
for uninfected and infected peptide pools were obtained (Figure
1A). First dimension mass spectrometric (MS1) ion maps showed
that the vast majority of ions were shared in the infected and
uninfected MS ion maps (Figure 1B). The peptides shared between
WNV infected and uninfected cells represent self peptides derived
from normal host proteins that are routinely sampled by class I
HLA regardless of the cells being infected or uninfected. Figure 1B
shows an ion map generated from HPLC fraction 50, where ion
466.7 was identified as unique to the WNV-infected peptide pools.
MS2 fragmentation was performed on ions unique to infected cells
and individual peptide sequences were determined (Figure 1C).
MS2 fragmentation at the same location in the corresponding
uninfected fraction (and neighboring uninfected fractions) con-
firmed the absence of this peptide in uninfected cells. Fragmen-
tation patterns between the newly discovered WNV-derived
peptides were compared to the MS2 fragmentation pattern of
the corresponding synthetic peptide to ensure amino acid
sequence fidelity. Figure 1C shows the MS2 fragmentation pattern
of ion 466.7 (identified as WNV-derived GTL9 peptide) overlaid
with a synthetic GTL9 peptide demonstrating a correct sequence
assignment. Finally, WNV derived peptides were assayed for their
binding affinity to HLA-A*11:01.
Figure 1D demonstrates that GTL9 is a high-affinity HLA-
A*11:01 ligand with an IC50 of 1132 nM. Using this direct
comparative approach, six HLA-A*11:01 WNV-derived peptides
were identified from four different viral proteins (C, NS3, NS4b,
and NS5) (Figure 2 and Table 2). Five peptides were nonamers
and one peptide was eleven amino acids in length.
These six WNV peptides fit the reported A*11:01-binding
motif. Five of the peptides (KSY9, AVV9, GTL9, RVL9 and
AII11) had a canonical A*11:01 P2 anchor residue of S, V, T or I;
only peptide KNM9 had a noncanonical asparagine at P2. At their
C terminus, A*11:01 peptide ligands prefer a lysine anchor, and
only GTL9 (C-terminal arginine) did not have a lysine C-terminal
anchor. When tested for binding to HLA-A*11:01, these six WNV
peptides were found to be high to medium-affinity binders with
RVL9 being the strongest binder, having an IC50 of 333.6 nM
(Table 2). The fluorescence polarization assay used to assess
A*11:01 binding categorizes peptides with IC50 values
,5,000 nM as high affinity. In summary, six WNV ligands were
discovered by direct elution from A*11:01, these ligands were
sequenced by tandem MS, their sequence was confirmed with
synthetic ligands, they bound well to A*11:01, they were of
traditional length, and these ligands were consistent with the
previously reported A*11:01 motif.
Class I HLA Sampling of Ligands within the WNV
Polyprotein
In addition to learning the number of viral ligands available for
immune surveillance, these data indicated the location of class I
HLA presented ligands within the WNV polyprotein. In our
previous survey of WNV, we found that A*02:01 presents six
peptides derived from five different proteins throughout the WNV
polyprotein (Figure 2 in black). Here, the HLA-A molecule
A*11:01 sampled six peptides derived from 4 viral proteins (Figure
Table 1. sHLA production after introduction of WNV into the
bioreactor.
Day Infection% sHLA Production (ng/mL)
1 1.31 21.34
2 10.02 16.25
3 61.85 14.27
4 87.21 4.12
5 81.74 NA
doi:10.1371/journal.pone.0066298.t001
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2 in red). Viral proteins NS3, NS4B and NS5 near the C-terminus
of the WNV polyprotein provided ligands for both A*11:01 and
A*02:01. The capsid viral protein at the N-terminus of the WNV
polyprotein provided the immune dominant A*11:01 GTL9
epitope and RVL9; this was distinct as no other HLA class I
molecules had been reported to sample a WNV capsid ligand.
While a trend emerged whereby N-terminal WNV proteins
provide immune dominant epitopes, more HLA than A2 & A11
would need to be studied to confirm this preliminary observation.
T Cell Recognition of A*11:01 WNV Ligands
In order to measure T cell reactivity to newly discovered WNV
ligands presented by the HLA-A*11:01 of the infected cells, CD8+
T cells from the peripheral blood mononuclear cells (PBMCs) of
twelve A*11:01 WNV-infected patients were stimulated first with a
pool of six identified WNV peptides for 9 days, then with each
individual peptide for 6 hours, after which T cell responses were
tested by intracellular cytokine staining (ICS).
Extended incubation of PBMC with WNV peptides was
undertaken for several reasons. First, PBMC were harvested from
WNV infected individuals a year or more following the patient’s
initial infection. When PBMC stimulated in vitro with specific
antigen are assessed for cytokine production, only recently primed
T cells tend to be detected [18]. Prolonged incubation of PBMC in
the presence of peptides is not uncommon when a subjects’ PBMC
are tested long after the peak of an acute infection [19–22].
Second, short term incubation of PBMC with peptides tend to
reveal dominant viral epitopes while extended cultures are more
likely to reveal epitopes that are otherwise undetectable or
marginally detectable [23]. Stimulation with the mixture of six
WNV peptides was deliberately chosen as the best approximation
of the natural setting where infected cells present multiple viral
epitopes. It has been demonstrated that this approach identifies a
CD8+ T cell hierarchy that closely resembles that seen after
natural infection [24]. Finally, the exposure of PBMC to a mixture
Figure 1. Direct epitope discovery of WNV epitope GTL9. (A) RP-HPLC profile of HLA-A*11:01 peptides from uninfected (blue) and WNV-
infected (red) cells. (B) MS ion spectra of HPLC fraction 50 from uninfected (black) and infected (red) cells. MS data were recorded for 300 scans. (C)
Overlay of the MS/MS fragmentation pattern of ion 466.7 in the infected HPLC fraction 50 (identified as the GTL9 peptide; red) with the MS/MS
fragmentation pattern for the GTL9 synthetic peptide (black). (D) Florescence polarization competitive binding assay with the GTL9 synthetic peptide
and HLA-A*11:01.
doi:10.1371/journal.pone.0066298.g001
Table 2. Identified WNV-derived peptides presented by HLA-
A*11:01.
Peptide Sequence Location Protein IC50 (nM)
KSY9 KSYETEYPK 1894 – 1902 NS3 7885
AVV9 AVVVNPSVK 2458 – 2466 NS4B 2254
GTL9 GTLTSAINR 89 – 97 C 1132
AII11 AIIEVDRSAAK 2559 – 2569 NS5 11235
RVL9 RVLSLIGLK 23 – 31 C 333.6
KNM9 KNMEKPGLK 2519 – 2527 NS4B 24333.0
doi:10.1371/journal.pone.0066298.t002
West Nile Virus T Cell Control Epitopes
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of peptide antigens in a short incubation yielded reactivity only to
the most dominant epitope (GTL9) among those discovered here
(data not shown). Extended T cell cultures were therefore the best
fit for testing dominant and subdominant WNV/HLA epitopes
with PBMC gathered approximately 1-year post infection.
In all twelve patients, CD3+/CD8+ T cell responses predom-
inated to GTL9 [mean: 15.39% of the CD3+/CD8+ cells were
positive for IFN-c] whereas mean responses to KSY9, AVV9,
AII11, RVL9, and KNM9 were 2.12%, 1.94%, 2.10%, 0.88%,
and 0.52%, respectively (negative control DMSO mean = 0.47%)
(Figure 3). The WNV peptide epitope KNM9 demonstrated
activity above the negative control only in one patient and RVL9
was similarly negative (Figure 4A). These data show that CTL
responses to these newly discovered HLA-A*11:01-restricted
WNV ligands fall into an immune dominant tier (GTL9), a
subdominant tier (KSY9, AVV9, & AII11), and an immunolog-
ically inert tier (RVL9 & KNM9). T cell responses to the dominant
T cell epitope were comparatively stronger than those to the T cell
mitogen SEB because extended incubation with the A11 peptides
proceeded for 9 days while stimulation with the SEB (positive
control) was performed for 6 hours at day 10.
Individually, T cells from all twelve of the A*11:01 subjects
responded to GTL9 (red) as the dominant epitope (Figure 4). As a
secondary subdominant epitope, T cells from four subjects
recognized KSY9 (blue), 3 recognized AVV9 (yellow), 3 recog-
nized AII11 (green) and 1 recognized RVL (purple) (Figure 4A). As
a tertiary epitope, three subjects recognized KSY9, 4 recognized
AII11 and 1 recognized AVV9. The CTL response to KSY9,
AVV9, and AII11 epitopes were not significantly different from
each other among the subjects (Figure 3) and different subjects
responded to these 3 epitopes as their second and third epitope at
approximately the same frequency. Individuals within this cohort
were consistent in their recognition of a dominant WNV epitope
yet demonstrated variability in their selection of secondary and
tertiary subdominant T cell epitopes.
T Cell Functional Response to A*11:01 WNV Epitopes
Accumulating data suggest that effective T cell control of
flaviviral infections requires anti-viral polyfunctional T cells to
secrete multiple cytokines and proliferate more readily on
encounter with antigen [25]. Polyfunctional T cells correlate
better with protective immunity to viruses than do single cytokine
secretors [25,26]. This includes reports of polyfunctional T cell
responses resulting from YFV 17D flaviviral vaccination [27]. To
investigate the polyfunctional characteristics of T cells from WNV
infected individuals, we stimulated PBMC from twelve A*11:01
infected individuals with the six WNV peptides reported here and
analyzed peptide-specific induction of IFN-c, TNF-a, IL-2, MIP-
1b and CD107a (a degranulation marker) in CD8+ T lymphocytes
(Figure 5).
Polyfunctional T cells producing $4 cytokines were observed in
20% of the total responding cells following stimulation with the
immunodominant GTL9 ligand (Figure 5). Subdominant epitopes
KSY9, AVV9, and AII11 induced production of 3–4 cytokines in
approximately 20% of responding T cells (Figure 5) and ligands
RVL9 and KNM9 induced production of 1–2 cytokines in a
majority of cells, with only 5% of the responding cells inducing 3
functions (Figure 5). Figure 6 provides polyfunctional T cell
responses for two representative individuals in the study, IDB-187
and IDS-095, while figure 7 illustrates the combined polyfunc-
tional response for two representative epitopes, GTL9 and
KNM9.
For each individual tested, IFN-c secreting polyfunctional T
cells specific for GTL9 were found at the highest frequency; this
was the primary, or immunodominant, response. For the
subdominant epitopes KSY9, AVV9, and AII11, no clear epitope
hierarchy was found in the patients tested; these lower secondary
responses were less polyfunctional with each individual displaying
a distinct secondary epitope response hierarchy (Figure 6). In
human populations, these data suggest that cellular immunity
commits to one epitope, A*11:01 GTL9. Furthermore, the
population does not commit to a secondary epitope, such that a
WNV GTL9 escape mutant would face different polyfunctional
immune pressure on epitopes KSY9, AVV9, and AII11 depending
upon the person infected.
Figure 2. Location of A*11:01 (red) and A*02:01 (black) WNV peptide epitopes on the WNV polyprotein. C, nucleocapsid; M, membrane;
E, envelope glycoprotein; NS, nonstructural.
doi:10.1371/journal.pone.0066298.g002
Figure 3. CTL reactivity of identified WNV epitopes. PBMC
isolated from naturally infected individuals were stimulated with a pool
of 6 WNV peptides in the presence of IL-2 for 9 days. On day 10, cultures
were restimulated with individual peptides for 6 h and T cell responses
were tested by Intracellular Cytokine Staining. Y-axis = %IFN-c positive
CD3+/CD8+ T cells. Each dot represents the response from a single WNV
subject. The average response to GTL9 was significantly higher than the
response to the negative control (DMSO). SEB: Staph Enterotoxin B *:
significant increase from negative control. Significance was determined
by one-way ANOVA followed by Tukey’s test; P,0.05.
doi:10.1371/journal.pone.0066298.g003
West Nile Virus T Cell Control Epitopes
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Discussion
Effective anti-viral immune responses tend to be tightly focused
on one or a few highly conserved immune epitopes. Factors
including epitope accessibility, B cell maturation, and T cell help
contribute to the formation of tightly focused neutralizing
antibodies [28–32]. In regards to cell mediated anti-viral
immunity, it is the class I HLA molecules, their intracellular
chaperones, and a number of intracellular proteolytic complexes
that are responsible for extracting a manageable number of
immune epitopes from an entire virus [33–38]. Once a ligand or
ligands are confirmed as presented by the HLA of virus-infected
cells, T cells can proceed to control viral infections via recognition
of one or more of the presented epitopes. The purpose of this study
was to first understand the number of WNV ligands that are
presented by the HLA of infected cells and to then measure T cell
reactivity to these ligands. It is our position that a firm
understanding of WNV ligand availability and T cell epitope
recognition will act as a cornerstone in the development of T cell
eliciting vaccines and therapies [39,40].
The first noteworthy observation of this study is that six WNV
derived peptide ligands are presented by HLA-A*11:01 molecules.
We previously reported that HLA-A*02:01 presents six WNV
ligands, however since A*02:01 peptides are difficult to enumerate
by mass spectroscopy because of their non-charged P2 and P9
ligand anchors, in this study we used A*11:01, a class I HLA-A
molecule that anchors peptides via an R or K at the C-terminus,
making it ideal for mass spectrometric characterization. Interest-
ingly, the A*02:01 results were reproduced with A*11:01. Both
HLA-A molecules reduced WNV polyprotein to a small number
of available immune ligands. As cellular immune responses are
largely effective in containing WNV infections, the HLA-A
presentation of a handful of viral ligands can now act as a
benchmark of immune success to which other viruses can be
compared for class I HLA ligand sampling.
As a segue to the discussion of how T cells manage the six
presented WNV ligands, it is worthwhile to consider the location
of HLA-A presented ligands within the WNV polyprotein. The
immune dominant A*11:01 epitope GTL9 comes from the WNV
capsid protein which is the most N-terminal viral protein. By
comparison, the dominant A*02:01 epitope SVG9 is derived from
the WNV envelope protein, and SVG9 is the most N-terminal A2
ligand detected. The N-terminal nature of these dominant
epitopes is consistent with the processing and presentation of
defective ribosomal products [41], although the fact that the most
N-terminal A*11:01 capsid ligand RVL9 is immunologically inert
shows that factors other than ribosome processing contribute to T
cell epitope selection. In contrast to the immunodominant GTL9
N-terminal ligand, the subdominant epitopes as well as the
immunologically inert ligands are found more towards the C-
terminal portion of the virus. These data suggest that immune
dominant WNV epitopes are more likely to be derived from the N-
terminus of the large flaviviral polyprotein and that less
immunogenic ligands will be located further downstream, towards
the C-terminus. If dominant viral T cell epitopes are indeed
located more towards the N-terminus of the viral polyprotein,
inclusion of WNV capsid in addition to matrix, and envelope
proteins for WNV vaccine constructs might worth considering.
Once we confirmed that a handful of ligands were presented by
class I HLA, the breadth and nature of T cell responses to these
ligands was tested.
On one end of the spectrum were dominant T cell responses to
GTL9. Each infected A*11:01 person dedicated a substantial
portion of their cellular immune response to this epitope and these
T cells were predominantly polyfunctional. Almost as one, WNV
Figure 4. Heterogeneity of CTL responses to WNV. A. PBMC isolated from subjects were stimulated with WNV peptides as described in
materials and methods and T cell responses were tested by Intracellular Cytokine Staining. Y-axis = %IFN-c positive CD3+/CD8+ T cells. Each bar
represents responses from CD3+/CD8+ T cells from each subject to the identified WNV peptides. GTL9 (red), KSY9 (blue), AII11 (green), AVV9 (yellow),
RVL9 (purple) and KNM9 (brown). Histograms represent patient-specific responses to WNV epitopes minus the negative control (DMSO) plus 26STD.
B. Number of patients that recognized each epitope.
doi:10.1371/journal.pone.0066298.g004
Figure 5. Peptide specific CD8+ responses from PBMC isolated
from 12 WNV infected subjects stimulated with peptides. Each
bar represents the mean percentage of the CD8+ T cells from all 12
donors that express 1 (purple), 2 (blue), 3 (green), 4 (yellow) or 5 (red
)markers [4 cytokines (IL-2, IFN-c, TNF-a, and MIP-1b) + degranulation
factor (CD107 a)] when exposed to each peptide.
doi:10.1371/journal.pone.0066298.g005
West Nile Virus T Cell Control Epitopes
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infected A*11:01 positive subjects focused polyfunctional T cells
on GTL9. These data parallel the A*02:01 positive subjects
response to SVG9 [42]. It has been proposed that polyfunctional
T cells, particularly those producing IFN-c, TNF-a, and IL-2,
correlate with protection and control of infectious diseases [19].
This appears to be the case with T cells that recognize the A*02:01
SVG9 epitope, as our previous work suggests that polyfunctional
CD8+ T cells to SVG9 correspond to the resolution of WNV
infections [42]. In a human vaccine trial, SVG9-specific polyfunc-
tional CD8+ T cells that produce IFN-c, TNF-a, and MIP-1b are
associated with the control of WNV replication a year following
vaccination [15]. Furthermore, Kim et. al. demonstrate that
incorporating the SVG9 peptide into a single chain HLA-A2
trimer DNA vaccine induces SVG9-specific CD8+ T cells that
protect from a lethal WNV challenge and that the adoptive
transfer of these T cells protects from infection in the absence of
humoral immunity [14]. Immunization of HLA transgenic mice, a
human vaccine trial, and adoptive T cell transfer combine to
demonstrate that T cells specific for the WNV immune dominant
HLA-A2/SVG9 epitope provide protective immunity.
So far, the immunodominant A*11:01 GTL9 epitope charac-
terized here demonstrates a startling similarity to A*02:01 SVG9.
The polyfunctional GTL9 specific CD8+ T cells tested here were
collected from individuals 1-year post infection, suggesting that
polyfunctional T cells specific to GTL9, like SVG9-specific T cells,
may contribute to protective immunity. While vaccine trials data
from animal models and human vaccine studies are not yet
available to confirm the role of GTL9-specific T cells in the
control of WNV infections, the similarities of A11/GTL9 and A2/
SVG9 make such vaccine studies a promising proposition.
In regards to the subdominant A*11:01 epitopes AII11, KSY9,
and AVV9, T cell responses varied from person-to-person in
Figure 6. Polyfunctional profiles of WNV-specific CD8+ T cells. All possible combinations of five functions (CD107a, IL-2, MIP-1b, IFN- c, and
TNF-a) produced by WNV epitope-specific CD8+ T cells are shown on the X-axis. Functional profiles are grouped and color-coded according to
number of functions and summarized in the pie charts. Each slice of the pie corresponds to the mean percentage of CD8+ T cells producing five (red),
four (dark blue), three (green), two (light blue), or one (yellow) function.
doi:10.1371/journal.pone.0066298.g006
West Nile Virus T Cell Control Epitopes
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e66298
regards to hierarchy, or percentage of responding T cells, and
monofunctional T cells tended to predominate for these subdom-
inant epitopes. As a population, WNV infected subjects differed in
their subdominant epitope hierarchy and in their polyfunctional T
cell phenotype as compared to GTL9. Were a WNV GTL9 escape
mutant to emerge, these data suggest that the population’s
resulting A*11:01 restricted T cell immunity would be evenly
split, with some individuals focusing on AII11, some on KSY9,
and other A*11:01 individuals focusing on AVV9. Knowledge of
these six WNV ligands allows one to visualize the full gradient of T
cell responses and provides a foundation for future studies of shifts
in T cell immunity that follow viral escape mutations at immune
dominant epitopes.
In the United States, by 11 December 2012, cases of WNV
infection surpassed that of any other year with 243 deaths, 597
viremic blood donors, and 5,387 cases [2]. It is not clear what
factors have led to such a high number of WNV infections in 2012,
but this pathogen is now classified as endemic to North America
and is likely here to stay due to an ideal combination of birds and
mosquitoes [2]. No vaccine or effective treatment is available for
WNV, but a number of prophylactic WNV immune therapies are
being tested [1]. Now that polyfunctional T cells have been
demonstrated to focus on the capsid-derived GTL9 ligand,
inclusion of the WNV capsid protein in addition to envelope
might worth considering in future YFV/WNV chimeric vaccines
to increase T cell immunogenicity and provide higher protection.
In summary, we report the systematic characterization of WNV
ligands eluted from the HLA-A*11:01 of virus infected cells. When
combined with our previous data for A*02:01, we see that two
distinct class I HLA found at high frequency in the population
present a small group of viral ligands and that A*02:01 and
A*11:01 are able to sample ligands from different viral proteins.
Given knowledge of the ligands presented on infected cells, a
spectrum of T cell responses then became apparent whereby
polyfunctional T cells recognizing a single viral epitope dominated
the cellular immune response to WNV. While all T cell responses
mediated by all HLA to all viruses may not follow the metric
illustrated here, these WNV data provide a benchmark of highly
effective WNV HLA antigen presentation and T cell immunity for
comparison to other HLA-mediated immune responses for other
pathogens. In addition, the A*11:01 data presented here are
consistent with a previous study whereby the immunodominant
A*02:01 SVG9 envelope epitope acted as a WNV correlate of
immunity and led to the successful testing of an SVG9 epitope
vaccine [14]. We are therefore optimistic that the immunodomiant
A*11:01 capsid-derived GTL9 ligand and the capsid antigen will
likewise contribute to next-generation West Nile virus immuno-
therapies.
Materials and Methods
Ethics Statement
Peripheral blood was collected from consenting subjects
diagnosed with WNV in heparinized tubes in accordance with a
protocol reviewed and approved by the Institutional Review Board
at the University of Pittsburgh. For all donors, written, informed
consent was obtained before enrollment into the study. The
Pittsburgh IRB was prepared in cooperation with the state of
Idaho Southwest District Health and the state of Idaho Central
District South Health Departments authorizing the University of
Pittsburgh IRB to be the IRB of record.
Figure 7. Combined polyfunctional response from 12 individuals to GTL9 and KNM9. PBMC from subjects were stimulated with GTL9 and
KNM9 peptide epitopes and functional responses were evaluated by multi-color flow cytometry (as described in materials and methods). Percentages
of CD8+ T cells expressing the markers shown were input in the SPICE software for display. Each slice of the pie corresponds to the mean percentage
of CD8+ T cells producing five (red), four (dark blue), three (green), two (light blue), or one (yellow) function. Horizontal bars represent the mean
percentage of CD8+ T cells producing different possible combinations of the 5 functions in response to the peptides.
doi:10.1371/journal.pone.0066298.g007
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Virus and Cell Culture
WNV strain WNV NY99 was propagated on Vero E6 cell
monolayers [American Type Culture Collection (ATCC) CRL-
1586]. Infected cell supernatant was cleared of cell debris by
centrifugation at 3,0006g for 15 min and stored at – 80uC. HeLa
(ATCC CCL-2) and Vero cells were subcultured according to
ATCC instructions in DMEM F12K (Wisent, Inc.), 10% FBS
(Serum Source International), and 1% penicillin/streptomycin
(Invitrogen).
sHLA-Secreting Transfectant Cell Line
HLA-A*11:01 cDNA was amplified by using a reverse
oligonucleotide primer that truncated the 39 end of exon 4,
deleting the transmembrane and cytoplasmic domains. Further-
more, the 39 reverse oligonucleotide primer included a VLDLr
purification epitope tag (SVVSTDDDLA) that is recognized by
the anti-VLDLr mAb (ATCC CRL-2197). The resulting PCR
product was cloned into pcDNA 3.1(–) (Invitrogen) and transfected
by Electroporation into HeLa cells. Quantification of sHLA in
supernatant was performed by using a sandwich ELISA, where an
antibody against the VLDLr epitope was the capture antibody, the
primary detector antibody was directed against b2-microglobulin
(Dako Cytomation).
Viral Detection
To confirm that HeLa cells were virus-infected, flow cytometry
was performed using E24 (Antibody against WNV envelope).
WNV infected cells were collected from the bioreactor (CP-2500
Hollow Fiber Bioreactor, Biovest Inc.) fixed in 70% Ethanol and
stored at –20uC until required for flow cytometry/FACS. Ethanol
was then removed and the cells were resuspended in Cell Staining
Buffer (PBS, 1% FBS, 0.01% NaN3) to allow rehydration. The
cells were pelleted again and incubated with AF 647-Conjugated
E24 (kindly provided by Dr. Michael Diamond, Washington
University, St. Louis, MO) at 4uC for 30 minutes. The cells were
then washed and resuspended in Cell Staining Buffer and
transferred to FACS tubes. Flow cytometry was performed using
a FACSCalibur flow cytometer (Becton Dickinson, Mountain
View, CA). Data files were acquired using BD CELLQuest 3.3
software and analyzed by flowJo V 7.8. (TreeStar Inc.).
Production and Isolation of HLA-A*11:01 Peptides
sHLA-A*11:01 peptide complexes were produced in a bioreac-
tor format as described [17,43,44]. To obtain sHLA from WNV-
infected cells, bioreactors containing HeLa cells were infected with
26108 pfu in a total volume of 200 ml (MOI < 361024) and
recirculated in the bioreactor for 2 h before the harvest of sHLA-
containing supernatant was initiated. Supernatant from days 0.5 to
5 after infection were pooled for purification because we needed
12 h to flush uninfected supernatant from the system. sHLA
complexes were purified by affinity chromatography with the anti-
VLDLr epitope antibody. Acid eluted peptides were lyophilized
and then fractionated by RP-HPLC with a Jupiter Proteo 90 A˚,
4 mm, 15062 column (Phenomenex) [16].
MS Analysis and Peptide-Binding Assay
MS ion maps were generated for HPLC fractions containing
peptides. Fractions were ionized by using nanoelectrospray
capillaries (Proxeon) into a QSTAR elite (Applied Biosystems)
electrospray quadrupole time-of-flight mass spectrometer. Peptide
sequences were determined manually by using the MASCOT
software package (Matrix Science). Peptide binding to HLA-
A*11:01 was determined using the florescence polarization
method (Pure Protein L.L.C.) [45].
WNV Patients and Samples
For this study PBMC were collected from 129 WNV infected
patients, recruited between March and June 2007 from high-
incidence areas in the central and southwest health districts of the
State of Idaho. The median age of cohort was 51 years, and the
range was 24–71 years. All persons had been diagnosed with
WNV in the summer of 2006, with confirmatory testing conducted
by the Idaho State Health Department. After collection, blood
samples were shipped overnight to Pittsburgh where PBMC were
isolated on Ficoll–Hypaque density gradients and cryopreserved in
10% DMSO. Hemolyzed blood samples or samples that had been
in transit for over 24 hours after collection were discarded. The
WNV serologic status of the Idaho cohort was further confirmed
by IgM/IgG ELISA testing by the Virology & Immunology
Section Pennsylvanya Department of Health Bureau of Labora-
tories.
HLA typing was completed using high resolution DNA
sequenced based typing in an ASHI/CLIA accredited clinical
HLA laboratory at the University of Oklahoma Health Sciences
Center and 12 patients were identified as A*11:01 positive of
which eleven had WNV fever without severe symptoms (non-
neuroinvasive disease) and one (IDS-056) had neuro-invasive
disease (encephalitis). This cohort was all North American and
A*11:01 allele frequency for North American Asian, Hispanic,
African American, and Caucasian peoples is 17.1%, 4.3%, 1.1%
and 6.3% respectively [46].
Extended T Cell Cultures
PBMC were thawed, allowed to recover for two hours at 37uC,
and then incubated for 9 days in the presence of a pool of six
A*11:01 WNV peptides (individual peptide concentration 1 mg/
ml) in complete medium (RPMI-1640; 10% heat inactivated fetal
calf serum, GemCell; 10 U/ml Penicillin and 10 mg/ml Strepto-
mycin; 25 nM HEPES). Interleukin 2 (500 U/ml, Prometheus
Laboratories Inc.) was added on day 3 and then again on day 7.
Cultures were washed twice to remove antigen and IL-2 on day 9
and rested in complete medium for 24 hours before performing
Intracellular Cytokine Staining (ICS).
Intracellular Cytokine Staining (ICS)
The polyfunctionality of stimulated T cells was determined by
intracellular cytokine staining (ICS) and flow cytometry. At the
end of the extended PBMC cultures, cells were incubated for
6 hours with individual peptides (10 mg/ml) or DMSO (as the
negative control) in the presence of extracellular transport
inhibitors (GolgiStop - GolgiPlug, BD). At the end of the
incubation period, cells were stained with the amine-binding dye
Aqua (Invitrogen) to identify and exclude of dead cells. Cells were
then surface stained with monoclonal antibodies to assign T cell
lineage (CD3-APC-H7; CD8-PerCP-Cy5.5; CD4-V450), and after
permeabilization with FACS Permeabilizing Solution 2 (BD), T
cell function (CD107a-FITC; MIP-1b-PE; IL-2-APC, TNFa-PE-
Cy7; IFN-c-AF700). All monoclonal antibodies were from BD
Bioscience. Events were acquired with a LSR-II 12-color flow
cytometer (BD Biosciences) and then analyzed using FlowJo V 7.8
(TreeStar Inc.). The cytometer performance and optimal PMT
voltages for individual channels were assessed by running CST
beads (BD) following the manufacturer’s recommendations. The
number of CD3+/CD8+ events gated for each stimulation was at
least 105 (Figure S1 for gating strategy). Positive gates for each of
the five functions (Figure S2) were drawn based on the negative
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control for each fluorescence channel (Figure S3). Boolean gate
arrays were created in FlowJo to determine the percentages of the
32 possible combinations (25) of the five functions we examined.
For each of the polyfunctional combinations, nonspecific back-
ground from the negative control was subtracted from the one
obtained from cultures incubated with peptide stimuli and
displayed using SPICE (Simplified Presentation of Incredibly
Complex Evaluations, Version 5.2, Mario Roederer, Vaccine
Research Center, NIAID, NIH).
Statistical Analysis
Significance was determined by one-way ANOVA followed by
Tukey’s method. A P value of ,0.05 was considered significant.
Statistical analysis was performed by using GraphPad Prism 5.0
software (GraphPad Software, Inc.)
Supporting Information
Figure S1 Flow cytometry gating strategy. Cells were
stimulated with the appropriate antigenic stimulus and stained as
detailed in the materials and methods section. Forward and side
scatters were used to gate in the lymphocyte population. This was
followed by exclusion of doublets by forward scatter area versus
height. Live cells only were then gated in by excluding events that
were positive for the amine binding dye excited by the violet laser.
CD3+/CD8+ double positive cells were gated in followed by
enumeration of positive cells for each immune functions (only IFN-
c is shown). Representative gating strategy for subject IDB-003 is
shown.
(TIF)
Figure S2 Functional responses to WNV epitope stimu-
lation. The dot plots show the gated CD3+/CD8+ events for each
of the five functions studied. Gates for each function were
positioned based on the negative control (DMSO). Representative
dot plots for subject IDB-003 are shown.
(TIF)
Figure S3 Flow cytometric analysis of CTL IFN-c
responses to WNV epitopes. Cultures were stimulated for
6 hours in the presence of the indicated stimuli and negative
control (DMSO). Cells were challenged with the individual
peptide epitopes after extended incubation with pools of WNV
peptide (as described in materials and methods). Percentages
shown in each dot plot indicate the magnitude of the response to
each stimulus as measured by IFN-c production by CD3+/CD8+
double positive cells. Representative experiment for subject IDB-
003 is shown.
(TIF)
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